NCT01406704View on ClinicalTrials.gov

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

PHASE4TerminatedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2013

Conditions

NASH (Non-alcoholic Steato-hepatitis)

Interventions

DRUG

Rosiglitazone

Rosiglitazone (8 mg/day)

DRUG

alpha-lipoic acid

alpha-lipoic acid (1800 mg/day)

DRUG

Rosiglitazone/alpha-lipoic acid

combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Seoul St. Mary's Hospital

OTHER